EF Hutton Acquisition Co. I Upgrades Artelo Biosciences (NASDAQ:ARTL) to “Strong-Buy”

EF Hutton Acquisition Co. I upgraded shares of Artelo Biosciences (NASDAQ:ARTL) to a strong-buy rating in a report published on Tuesday, Zacks.com reports.

Separately, HC Wainwright restated a buy rating and set a $5.00 price objective on shares of Artelo Biosciences in a research note on Wednesday, August 14th.

Artelo Biosciences Price Performance

NASDAQ ARTL opened at $1.12 on Tuesday. The stock’s 50 day moving average is $1.23 and its 200 day moving average is $1.34. The firm has a market capitalization of $3.60 million, a PE ratio of -0.35 and a beta of 1.36. Artelo Biosciences has a twelve month low of $1.00 and a twelve month high of $1.78.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.10. On average, research analysts anticipate that Artelo Biosciences will post -2.41 earnings per share for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.